LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Home・Akciju saraksts・Editas Medicine Inc

Editas Medicine Inc

Slēgts

SektorsVeselības aprūpe

2.19 7.35

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.01

Max

2.27

Galvenie mērījumi
By Trading Economics
Ienākumi	28M -25M
Pārdošana	4M 7.5M
Peļņas marža	-332.984
Darbinieki	246
EBITDA	27M -22M

Rekomendācijas
By TipRanks
Rekomendācijas	Pārdot
Prognoze 12 mēnešiem	+86.05% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-65M 210M
Iepriekšējā atvēršanas cena	-5.16
Iepriekšējā slēgšanas cena	2.19

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.33 / 1.54 Atbalsts un pretestība

Editas Medicine Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. marts 23:39 UTC

Karstas akcijas

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

2026. g. 4. marts 23:20 UTC

Peļņas

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

2026. g. 4. marts 21:43 UTC

Peļņas

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

2026. g. 4. marts 23:48 UTC

Tirgus saruna

Nikkei May Rise After Recent Selloffs -- Market Talk

2026. g. 4. marts 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

2026. g. 4. marts 23:24 UTC

Tirgus saruna

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

2026. g. 4. marts 22:30 UTC

Peļņas

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

2026. g. 4. marts 22:30 UTC

Peļņas

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

2026. g. 4. marts 22:30 UTC

Peļņas

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

2026. g. 4. marts 22:13 UTC

Peļņas

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

2026. g. 4. marts 22:13 UTC

Peļņas

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

2026. g. 4. marts 22:13 UTC

Peļņas

Vermilion Energy 4Q EPS C$2.86 >VET

2026. g. 4. marts 22:04 UTC

Tirgus saruna

RBA Slipping Behind The Curve On Rates -- Market Talk

2026. g. 4. marts 21:53 UTC

Peļņas

Lithium Americas 4Q Rev $66.8M >LAC

2026. g. 4. marts 21:53 UTC

Peļņas

Lithium Americas 4Q Loss/Shr 52c >LAC

2026. g. 4. marts 21:52 UTC

Peļņas

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

2026. g. 4. marts 21:50 UTC

Peļņas

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

2026. g. 4. marts 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 4. marts 21:48 UTC

Peļņas

Webull 4Q Rev $165.2M >BULL

2026. g. 4. marts 21:48 UTC

Peļņas

Webull 4Q EPS 1c >BULL

2026. g. 4. marts 21:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 4. marts 21:45 UTC

Tirgus saruna

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

2026. g. 4. marts 21:40 UTC

Peļņas

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

2026. g. 4. marts 21:36 UTC

Galvenie ziņu notikumi

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

2026. g. 4. marts 21:27 UTC

Peļņas

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

2026. g. 4. marts 21:17 UTC

Tirgus saruna

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

2026. g. 4. marts 21:16 UTC

Peļņas

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

2026. g. 4. marts 21:15 UTC

Peļņas

Broadcom 1Q EPS $1.50 >AVGO

2026. g. 4. marts 21:15 UTC

Peļņas

Broadcom 1Q Net $7.35B >AVGO

2026. g. 4. marts 21:15 UTC

Peļņas

Broadcom 1Q Rev $19.31B >AVGO

Salīdzinājums

Cenas izmaiņa

Editas Medicine Inc Prognoze

Cenas mērķis

By TipRanks

86.05% augšup

Prognoze 12 mēnešiem

Vidējais 4 USD 86.05%

Augstākais 4 USD

Zemākais 4 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Editas Medicine Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pārdot

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Editas Medicine Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.33 / 1.54Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.